Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 106)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 389.988
Gesamt: 389.988
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X
6,9100
EUR
-0,58 %
-0,0400 EUR
Letzter Kurs 07.05.24 Lang & Schwarz
Neuigkeiten
02.05.24 · Accesswire  |
25.04.24 · wO Chartvergleich |
11.04.24 · Accesswire |
11.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 | |
| 1,2100 | +21,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,2500 | -19,23 | |
| 1,4500 | -20,98 | |
| 0,7500 | -27,88 | |
| 0,7240 | -42,43 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Mit dem Orakeln aus den Calls und Put´s kenne ich mich nicht aus.
Da muss es ja irgend welche Portale und Seiten geben, wo man das sehen kann?
Wer kennt sich damit aus und vermag mich da mal zu erhellen?
Da muss es ja irgend welche Portale und Seiten geben, wo man das sehen kann?
Wer kennt sich damit aus und vermag mich da mal zu erhellen?
Wer macht mit beim Wetten?
1. SK
Mein Tipp:
2. Die Americanbulls haben heute auf Kaufen gewechselt, sehe ich aber erst ab 00:30 die Nacht.
Wer hält dagegen?
1. SK
Mein Tipp:
2. Die Americanbulls haben heute auf Kaufen gewechselt, sehe ich aber erst ab 00:30 die Nacht.
Wer hält dagegen?
https://www.briefing.com/Investor/PopupPages/ArticlePopup.as…
Welcome @Briefingcom Followers!
$VRX: Valeant Pharma: Salix presents new investigational data from a post-hoc analysis of Phase 3 safety data evaluating the effect of rifaximin on risk of infections in a randomized, placebo-controlled trial of repeat treatment in adults with irritable bowel syndrome with diarrhea (22.08)
Welcome @Briefingcom Followers!
$VRX: Valeant Pharma: Salix presents new investigational data from a post-hoc analysis of Phase 3 safety data evaluating the effect of rifaximin on risk of infections in a randomized, placebo-controlled trial of repeat treatment in adults with irritable bowel syndrome with diarrhea (22.08)
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering,
https://ih.advfn.com/p.php?pid=nmona&article=77577249https://ih.advfn.com/p.php?pid=nmona&article=77576464
Trading Spotlight
Valeant, Endo Both Buys in Specialty Pharma
https://www.barrons.com/articles/valeant-endo-both-buys-in-s…
https://www.chartmill.com/analyze.php?utm_source=stocktwits&…
Offensichtliche "Weisheiten" der Chartlinien noch mal schön dargestellt.
Letztendes gilt die alte Chartweisheit: "Wenn der Hahn kräht auf dem Mist, ändert sich der Kurs..."
Nach beiden Seiten ist nun ordentlich Luft. Mehr als einmal wurde eine Erholung kaputt geshortet.
Aber bei einem "Turnaround", auf den hier die letzten Verbliebenen noch hoffen, könnte noch ein Faktor 2-3 realistisch sein.
Wenn da mal nicht wieder kurzfristig so eine kleine Reiberei in der Ukraine während der WM die allgemeine Stimmung drücken tut.
Offensichtliche "Weisheiten" der Chartlinien noch mal schön dargestellt.
Letztendes gilt die alte Chartweisheit: "Wenn der Hahn kräht auf dem Mist, ändert sich der Kurs..."
Nach beiden Seiten ist nun ordentlich Luft. Mehr als einmal wurde eine Erholung kaputt geshortet.
Aber bei einem "Turnaround", auf den hier die letzten Verbliebenen noch hoffen, könnte noch ein Faktor 2-3 realistisch sein.
Wenn da mal nicht wieder kurzfristig so eine kleine Reiberei in der Ukraine während der WM die allgemeine Stimmung drücken tut.
Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017.
https://www.ncbi.nlm.nih.gov/pubmed/29844795
Abstract
Diverticulosis is a common anatomical condition, which appears to be age-dependent. Individuals who develop chronic gastrointestinal symptoms or complications are referred to as having diverticular disease. Although the diagnosis of this condition can be relatively straightforward, randomized controlled trials are scarce and management often follows tradition rather than principles of evidence-based medicine. This report deals with the topics discussed during a symposium held during the United European Gastroenterology Week (Barcelona, October 2017). During the meeting, the role of dysbiosis in the pathogenesis of diverticular disease and its treatment were thoroughly discussed, by examining the efficacy and mechanisms of action of the currently used drugs. Recent studies have shown the presence of dysbiosis in patients with diverticular disease and suggest an imbalance in favor of bacteria with pro-inflammatory and pathogenetic potential. These microbiota changes correlate with mucosal immune activation, mirrored by a marked increase of macrophages in colonic mucosa, both in the diverticular region and at distant sites. The low-grade inflammation, driven by bacteria-induced immune activation, could be involved in the pathophysiology of symptoms. As a consequence, pharmacological approaches targeting enteric bacteria (with poorly absorbed antibiotics, like rifaximin, or probiotics) or intestinal inflammation (with 5-ASA derivatives or rifaximin) have shown capability of controlling symptoms and also preventing complications, albeit more research is needed to establish the optimal regimen (daily dose and duration) of therapy. Well-designed randomized-controlled trials (RCTs), including homogeneous populations of patients, are therefore needed. The future of management of many GI diseases, including symptomatic uncomplicated diverticular disease, will rely on the so-called 'microbiota-directed therapies'.
https://www.ncbi.nlm.nih.gov/pubmed/29844795
Abstract
Diverticulosis is a common anatomical condition, which appears to be age-dependent. Individuals who develop chronic gastrointestinal symptoms or complications are referred to as having diverticular disease. Although the diagnosis of this condition can be relatively straightforward, randomized controlled trials are scarce and management often follows tradition rather than principles of evidence-based medicine. This report deals with the topics discussed during a symposium held during the United European Gastroenterology Week (Barcelona, October 2017). During the meeting, the role of dysbiosis in the pathogenesis of diverticular disease and its treatment were thoroughly discussed, by examining the efficacy and mechanisms of action of the currently used drugs. Recent studies have shown the presence of dysbiosis in patients with diverticular disease and suggest an imbalance in favor of bacteria with pro-inflammatory and pathogenetic potential. These microbiota changes correlate with mucosal immune activation, mirrored by a marked increase of macrophages in colonic mucosa, both in the diverticular region and at distant sites. The low-grade inflammation, driven by bacteria-induced immune activation, could be involved in the pathophysiology of symptoms. As a consequence, pharmacological approaches targeting enteric bacteria (with poorly absorbed antibiotics, like rifaximin, or probiotics) or intestinal inflammation (with 5-ASA derivatives or rifaximin) have shown capability of controlling symptoms and also preventing complications, albeit more research is needed to establish the optimal regimen (daily dose and duration) of therapy. Well-designed randomized-controlled trials (RCTs), including homogeneous populations of patients, are therefore needed. The future of management of many GI diseases, including symptomatic uncomplicated diverticular disease, will rely on the so-called 'microbiota-directed therapies'.
Antwort auf Beitrag Nr.: 57.884.892 von marty44 am 01.06.18 10:48:39New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
https://www.ncbi.nlm.nih.gov/pubmed/29807873
Abstract
Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients' quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.
https://www.ncbi.nlm.nih.gov/pubmed/29807873
Abstract
Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients' quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.
Durchsuchen
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
04.03.24 · wO Chartvergleich · Myriad Genetics |